Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: the OPUS-2 study. (Q52567183)
Jump to navigation
Jump to search
scientific article published on 24 April 2018
Language | Label | Description | Also known as |
---|---|---|---|
English | Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: the OPUS-2 study. |
scientific article published on 24 April 2018 |
Statements
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study (English)
E Aygören-Pürsün
J Baker
J Anderson
P Busse
M Manning
M Magerl
M Gompels
A P Huissoon
H Longhurst
W Lumry
B Ritchie
R Shapiro
D Soteres
M Cancian
D T Johnston
T J Craig
H H Li
M Liebhaber
T Nickel
J Offenberger
R Schrijvers
M Triggiani
H J Wedner
S Dobo
M Cornpropst
D Clemons
L Fang
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference